View Future GrowthBio-Gate 과거 순이익 실적과거 기준 점검 0/6Bio-Gate 의 수입은 연평균 -20%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 4.4%의 비율로 감소했습니다. 매출은 연평균 7.9%의 비율로 증가해 왔습니다.핵심 정보-20.04%순이익 성장률-14.20%주당순이익(EPS) 성장률Chemicals 산업 성장률12.41%매출 성장률7.93%자기자본이익률-156.60%순이익률-19.71%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.모든 업데이트 보기Recent updatesNew Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€5.81m market cap, or US$6.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€809k free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€7.74m market cap, or US$9.14m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).공지 • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.New Risk • Aug 03New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.3m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€8.74m market cap, or US$10.1m).Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.New Risk • Jul 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.37m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.37m market cap, or US$9.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Mar 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€6.52m market cap, or US$7.05m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.9% average weekly change).New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).매출 및 비용 세부 내역Bio-Gate가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:BIG1 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 257-13031 Mar 257-13031 Dec 247-23030 Sep 247-23030 Jun 248-23031 Mar 247-23031 Dec 237-23030 Sep 237-23030 Jun 237-13031 Mar 236-23031 Dec 226-23030 Sep 226-23030 Jun 226-23031 Mar 226-13031 Dec 216-12030 Sep 216-12030 Jun 216-12031 Mar 216-12031 Dec 205-12030 Sep 205-12030 Jun 205-12031 Mar 204-12031 Dec 194-12030 Sep 193-12030 Jun 193-12031 Mar 194-12031 Dec 184-12030 Sep 184-12030 Jun 18502031 Mar 18402031 Dec 17402030 Sep 17402030 Jun 17402031 Mar 17402031 Dec 16401030 Sep 16401030 Jun 16401031 Mar 16301031 Dec 153-11030 Sep 153-11030 Jun 153-110양질의 수익: BIG1 은(는) 현재 수익성이 없습니다.이익 마진 증가: BIG1는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BIG1은 수익성이 없으며 지난 5년 동안 손실이 연평균 20% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BIG1의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BIG1은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-2.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BIG1는 현재 수익성이 없으므로 자본 수익률이 음수(-156.6%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 03:48종가2026/05/07 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bio-Gate AG는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Cosmin FilkerGBC AGMatthias GreiffenbergerGBC AG
Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€5.81m market cap, or US$6.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€809k free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€7.74m market cap, or US$9.14m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
공지 • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.
New Risk • Aug 03New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.3m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (€8.74m market cap, or US$10.1m).
Reported Earnings • Aug 03Full year 2024 earnings releasedFull year 2024 results: Revenue: €7.21m (down 1.3% from FY 2023). Net loss: €1.62m (flat on FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany.
New Risk • Jul 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.37m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€8.37m market cap, or US$9.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Mar 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€6.52m market cap, or US$7.05m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.9% average weekly change).
New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).